BioLife Wins US Patent for Effervescent Oral Peptide Delivery Platform
BioLife has received a US patent for an effervescent tablet technology intended to enable oral delivery of peptide therapeutics, including GLP-1 receptor agonists used in the treatment of obesity and metabolic disease. BioLife’s proprietary oral peptide delivery technology is designed to create a temporary gastric buffering environment that may help protect peptide molecules as they pass through the gastrointestinal tract.
The patent comes as pharmaceutical developers continue to pursue oral alternatives to injectable peptide therapies. GLP-1 medicines generated an estimated $132 billion in global sales in 2025, according to figures cited by BioLife, while the market for obesity medicines was estimated at approximately $42 billion.
The technology, developed under the internal name OralMatrix, uses a dissolvable effervescent tablet rather than relying primarily on specialized coatings or absorption-enhancing excipients. According to the company, dissolution of the formulation produces a gastric buffer intended to help shield peptide molecules during gastrointestinal transit and facilitate subsequent absorption.
Farid Bennis, founder of BioLife and inventor of the technology, says the patent reflects more than formulation protection, pointing to the company’s longer-term objective of addressing the difficulty of transporting peptide therapeutics through the digestive system.
BioLife reports that preclinical studies with its platform produced measurable systemic exposure to semaglutide following oral administration. The finding provides an in vivo proof of concept for the company’s approach, although the results remain preclinical and do not establish clinical efficacy or safety in humans.
The granted patent claims extend beyond semaglutide to a number of GLP-1 receptor agonists, including liraglutide, dulaglutide, albiglutide, exenatide and lixisenatide. BioLife says the US patent provides protection through 2042, while additional patent applications remain pending in international markets.
BioLife emphasized that the technology remains in development and has not been approved for the treatment of any disease. The company’s reported semaglutide findings are based on preclinical studies and will require further development and clinical evaluation before any conclusions can be drawn about use in patients.
For more information, visit https://biolife.bio/.
Total Page Views: 3
